Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Genetics

• Publication date

  2013-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cancergen.2013.01.003PMID 23531595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

  2013cited by this paper
• Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone

  2013cited by this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cited by this paper
• Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

  2012cited by this paper
• Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14

  2012cited by this paper
• NOTCH1 mutations in CLL associated with trisomy 12.

  2012cited by this paper
• Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

  2012cited by this paper
• Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

  2012cited by this paper
• NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

  2012cited by this paper
• Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.

  2012cited by this paper
• Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations

  2012cited by this paper
• Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling.

  2012cited by this paper
• Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia

  2012cited by this paper
• Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.

  2012cited by this paper
• The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

  2012cited by this paper
• Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.

  2011cited by this paper
• B‐cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage

  2011cited by this paper
• 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia

  2011cited by this paper
• SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

  2011cited by this paper
• Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia

  2011cited by this paper
• 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia

  2011cited by this paper
• Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

  2011cited by this paper
• Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

  2011cited by this paper
• Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

  2011cited by this paper
• Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

  2011cited by this paper
• Novel therapeutic agents for B-cell lymphoma: developing rational combinations.

  2011cited by this paper
• Adverse prognostic features in chronic lymphocytic leukemia.

  2011cited by this paper
• Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

  2011cited by this paper
• Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

  2011cited by this paper
• Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

  2011cited by this paper
• Genome‐wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia

  2011cited by this paper
• Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia

  2011cited by this paper
• MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Histone deacetylases and epigenetic therapies of hematological malignancies.

  2010cited by this paper
• microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

  2010cited by this paper
• Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies

  2010cited by this paper
• Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.

  2010cited by this paper
• Critical role of microRNAs in chronic lymphocytic leukemia: overexpression of the oncogene PLAG1 by deregulated miRNAs

  2010cited by this paper
• Deletion of 5q as a rare abnormality in chronic lymphocytic leukemia.

  2010cited by this paper
• Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

  2010cited by this paper
• A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B‐chronic lymphocytic leukaemia

  2010cited by this paper
• Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.

  2010cited by this paper
• TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

  2010cited by this paper
• Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.

  2010cited by this paper
• Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

  2010cited by this paper
• From pathogenesis to treatment of chronic lymphocytic leukaemia

  2010cited by this paper
• Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

  2010cited by this paper
• Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients

  2010cited by this paper
• TP53 mutation and survival in chronic lymphocytic leukemia.

  2010cited by this paper
• The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

  2010cited by this paper
• Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

  2010cited by this paper
• How I treat CLL up front.

  2010cited by this paper
• Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.

  2009cited by this paper
• Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.

  2009cited by this paper
• Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells.

  2009cited by this paper
• microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification.

  2009cited by this paper
• Patterns of microRNA expression characterize stages of human B-cell differentiation.

  2009cited by this paper
• Evaluation of 13q14 status in patients with chronic lymphocytic leukemia using single nucleotide polymorphism-based techniques.

  2009cited by this paper
• Prognostic markers in chronic lymphocytic leukemia: a comprehensive review.

  2009cited by this paper
• Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization.

  2009cited by this paper
• Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

  2009cited by this paper
• MicroRNAs in Cancer.

  2009cited by this paper
• The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness

  2009cited by this paper
• Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA).

  2009cited by this paper
• The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

  2009cited by this paper
• Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

  2009cited by this paper
• Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

  2009cited by this paper
• A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia

  2009cited by this paper
• Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

  2009cited by this paper
• Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.

  2009cited by this paper
• Causes and consequences of microRNA dysregulation in cancer

  2009cited by this paper
• miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.

  2009cited by this paper
• Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin‐2 stimulation: A Belgian multicentric study

  2009cited by this paper
• Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.

  2008cited by this paper
• Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

  2008cited by this paper
• Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion

  2008cited by this paper
• Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

  2008cited by this paper
• Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients

  2008cited by this paper
• Genomic complexity in chronic lymphocytic leukemia.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• MiR-15a and miR-16-1 cluster functions in human leukemia

  2008cited by this paper
• De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

  2008cited by this paper
• Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome.

  2008cited by this paper
• Chronic lymphocytic leukaemia.

  2008cited by this paper
• Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia

  2008cited by this paper
• Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.

  2008cited by this paper
• Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

  2008cited by this paper
• Molecular allelokaryotyping of early‐stage, untreated chronic lymphocytic leukemia

  2008cited by this paper
• Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia.

  2008cited by this paper
• Disease burden of chronic lymphocytic leukaemia within the European Union

  2008cited by this paper
• Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis

  2008cited by this paper
• MicroRNA targeting specificity in mammals: determinants beyond seed pairing.

  2007cited by this paper
• Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

  2007cited by this paper
• Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.

  2007cited by this paper
• Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping

  2007cited by this paper
• Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

  2007cited by this paper
• Hypermethylation of the p15INK4B gene promoter in B‐chronic lymphocytic leukemia

  2007cited by this paper

• Complex genetic landscape in CLL: Clinical impact on patients’ survival and insights into the altered molecular pathways

  2025cites this paper
• POPULATION AGING AND THE RISE OF REFRACTORY LEUKEMIAS: SURVEILLANCE, SCREENING AND STRATEGIC HEALTH PLANNING

  2025cites this paper
• The ABCs of IGHV Testing in Chronic Lymphocytic Leukaemia: Current Recommendations, Ongoing Challenges, and Future Directions.

  2025cites this paper
• CD20+ T cells in monoclonal B cell lymphocytosis and chronic lymphocytic leukemia: frequency, phenotype and association with disease progression

  2024cites this paper
• Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game

  2024cites this paper
• The Research Advances of Aptamers in Hematologic Malignancies

  2023cites this paper
• PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia

  2023cites this paper
• Expression of LAG-3 on B-lymphocytes as a marker for prediction of response to therapy in patients with chronic lymphocytic leukemia

  2023cites this paper
• CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies

  2023cites this paper
• Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia

  2023cites this paper
• Expression profile of immunophenotypic marker molecules on B-lymphocytes in patients with chronic lymphocytic leukemia at the stages of immunochemotherapy

  2022cites this paper
• CRISPR/Cas9 in Chronic Lymphocytic Leukemia

  2022cites this paper
• Risk Factors of White Blood Cell Progression Among Patients With Chronic Lymphocytic Leukemia at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia

  2022cites this paper
• Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application

  2021cites this paper
• The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment

  2021cites this paper
• MYD88 Gene Polimorphism in Patients With Chronic Lenfoid Leukemia

  2021cites this paper
• ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both?

  2021cites this paper
• An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia

  2021cites this paper
• CAR T-Cell Therapy in Hematological Malignancies

  2021cites this paper
• Expression of Surface-associated 82 kDa proMMP-9 in Lymphatic Leukemia Blast Cells Differentially Correlates With Prognosis

  2021cites this paper
• The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment

  2021cites this paper
• B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making

  2020cites this paper
• Variability within the human TERT gene, telomere length and predisposition to chronic lymphocytic leukemia

  2019cites this paper
• Applications of fluorescence in situ hybridization in detection of disease biomarkers and personalized medicine

  2019cites this paper
• Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors

  2019cites this paper
• Hibridación in situ fluorescente (FISH) en el Instituto Nacional de Cancerología (INC) de Colombia. Experiencia de 5 años

  2019cites this paper
• OTT_A_198313 4309..4320

  2019cites this paper
• Advances in chronic lymphocytic leukemia pharmacotherapy.

  2018cites this paper
• Informe de Posicionamiento Terapéutico de venetoclax (Venclyxto®) en leucemia linfocítica crónica

  2018influential citation
• Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia

  2018cites this paper
• The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia.

  2018cites this paper
• Characterization of Chronic Lymphocytic Leukemia by aCGH/MLPA

  2018influential citation
• Cohesin RAD21 Gene Promoter Methylation in Patients with Chronic Lymphocytic Leukemia

  2018cites this paper
• ZAP-70 Expression in B-Chronic Lymphocytic Leukemia in Sudanese Patients

  2018cites this paper
• ZAP 70 ( zeta-chain ( TCR ) associated protein kinase 70 kDa )

  2018cites this paper
• The Effect of NOP16 Mutation in Chronic Lymphocytic Leukemia

  2017cites this paper
• Chapter 8 New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia

  2017cites this paper
• Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients

  2017cites this paper
• Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL

  2017cites this paper
• Lymphocytic Leukemia B Cells Obinutuzumab ( GA 101 ) in Chronic Effector Functions of Rituximab and Role for ZAP-70 Signaling in the Differential

  2017cites this paper
• Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells

  2017cites this paper
• Genomic data integration in chronic lymphocytic leukemia

  2017cites this paper
• MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia

  2017cites this paper
• Wilms' tumor gene 1 in leukemia: Prognostic or predictive biomarker

  2017cites this paper
• Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

  2017cites this paper
• ROR1 as a target for cancer immunotherapy

  2017cites this paper
• Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis

  2017cites this paper
• A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

  2016influential citation
• Comprehensive Genetic Analysis by Integration of Conventional Karyotyping and Interphase FISH Helps Refinement of Biological Subclasses with Clinical Impact in Chronic Lymphocytic Leukemia

  2016cites this paper
• Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia–Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears

  2016cites this paper
• BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients

  2016cites this paper
• Twist as a new prognostic marker in hematological malignancies

  2016cites this paper
• Somatic Mutation in Immunoglobulin Gene Variable Region in Patients With Chronic Lymphoid Leukemia and Its Influence on Disease Prognosis

  2016cites this paper
• MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.

  2016cites this paper
• Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?

  2015cites this paper
• A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia

  2015cites this paper
• Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway

  2015cites this paper
• Neutropenia in cancer patients, risk prediction models of neutropenia, and supportive measures

  2015cites this paper
• New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia

  2015cites this paper
• The Cancer Genomics Resource List 2014.

  2015cites this paper
• Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.

  2015cites this paper
• Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis

  2015cites this paper
• Isochromosome 17q in Chronic Lymphocytic Leukemia

  2015cites this paper
• IGFBP-2 - taking the lead in growth, metabolism and cancer

  2015cites this paper
• Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.

  2015cites this paper
• Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)

  2015cites this paper
• Molecular Genetics of Chronic Lymphocytic Leukaemia

  2014cites this paper
• Investigation of circulating lncRNAs in B-cell neoplasms.

  2014cites this paper
• Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

  2014cites this paper
• Université de Montréal-Thèse numérique

  2014cites this paper
• 1 Protein kinase C ( PKC ) as a drug target in chronic lymphocytic leukemia

  2014cites this paper
• Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine

  2014cites this paper
• Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH)

  2014influential citation
• Molecular genetic studies on Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia - with focus on prognostic markers

  2014cites this paper
• DNA Methylation Biomarkers: Cancer and Beyond

  2014cites this paper
• Mutation Status and Immunoglobulin Gene Rearrangements in Patients from Northwest and Central Region of Spain with Chronic Lymphocytic Leukemia

  2014cites this paper
• Somatic Mutation in Immunoglobulin Gene Variable Region in Patients with Chronic Lymphoid Leukemia and its Influence on Patients' Prognosis in Irany

  2013cites this paper
• Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia

  2013cites this paper
• Generation of Eμ-PKCβII transgenic mice for the study of chronic lymphocytic leukaemia (CLL)

  2013cites this paper
• Developments in the immunophenotypic analysis of haematological malignancies.

  2013cites this paper
• Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview

  2013cites this paper
• Research Progress on the Anti-Leukemia Effect of Lycorine

  2013cites this paper
• Omega-3 Fatty Acids as Therapeutic Options for the Treatment of B-cell Chronic Lymphocytic Leukemia

  2013cites this paper
• International Journal of Molecular Sciences Quantitative Proteomics to Characterize Specific Histone H2a Proteolysis in Chronic Lymphocytic Leukemia and the Myeloid Thp-1 Cell Line

  year unknowncites this paper